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Abstract: Background: SerpinB3 (SB3) is a hypoxia and hypoxia-inducible factor (HIF)-2α-dependent
cysteine-protease inhibitor up-regulated in hepatocellular carcinoma (HCC), released by cancer cells
and able to stimulate proliferation and epithelial-to-mesenchymal-transition. Methods: In the study
we employed transgenic and knock out SerpinB3 mice, liver cancer cell line, human HCC specimens,
and mice receiving diethyl-nitrosamine (DEN) administration plus choline-deficient L-amino acid
refined (CDAA) diet (DEN/CDAA protocol). Results: We provide detailed and mechanistic evidence
that SB3 can act as a paracrine mediator able to affect the behavior of surrounding cells by differentially
up-regulating, in normoxic conditions, HIF-1α and HIF-2α. SB3 acts by (i) up-regulating HIF-1α
transcription, facilitating cell survival in a harsh microenvironment and promoting angiogenesis,
(ii) increasing HIF-2α stabilization via direct/selective NEDDylation, promoting proliferation of liver
cancer cells, and favoring HCC progression. Moreover (iii) the highest levels of NEDD8-E1 activating
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enzyme (NAE1) mRNA were detected in a subclass of HCC patients expressing the highest levels
of HIF-2α transcripts; (iv) mice undergoing DEN/CDAA carcinogenic protocol showed a positive
correlation between SB3 and HIF-2α transcripts with the highest levels of NAE1 mRNA detected
in nodules expressing the highest levels of HIF-2α transcripts. Conclusions: These data outline
either HIF-2α and NEDDylation as two novel putative therapeutic targets to interfere with the
procarcinogenic role of SerpinB3 in the development of HCC.
Keywords: SerpinB3; hypoxia; hypoxia inducible factors HIF-1α and HIF-2α; HCC; NEDD8; NEDDylation
1. Introduction
SerpinB3 (SB3) is a serine protease inhibitor up-regulated in several malignancies of epithelial
origin [1,2], including hepatocellular carcinoma (HCC) [1,3]. SB3, virtually undetectable in normal
hepatocytes, is up-regulated in cirrhotic livers, dysplastic nodules, HCC [1–4] and hepatoblastoma [5],
and proposed to be involved in early carcinogenesis [6]. In liver cancer cells, by acting as an
autocrine and/or paracrine mediator, SB3 induces apoptosis resistance [7], cell proliferation [8],
epithelial-to-mesenchymal transition (EMT), and increased invasiveness [9,10]. Moreover, SB3 is
up-regulated by oncogenic Ras and promotes NF-kB-dependent expression of inflammatory cytokines,
autocrine IL-6 signaling [10,11] as well as c-Myc expression through the Yap pathway [12], all events
potentially favoring tumor progression. In addition, SB3 transcription, synthesis, and extracellular
release are up-regulated by hypoxia through selective HIF-2α-dependent and redox-sensitive
mechanisms in liver cancer cells, with a relevant positive correlation between HIF-2α and SB3
transcript levels in human HCC specimens, related to early recurrence [13].
Along these lines, tumor hypoxia is considered as an independent negative prognostic indicator
with a significant risk for the patient to develop metastasis that may escape therapy [14,15]. Hypoxic
microenvironment is also believed to contribute to cancer progression by activating adaptive
transcriptional programs involved in promoting angiogenesis, EMT, and increased invasiveness
in human epithelial cancer cells [16–19]. In this scenario, hypoxia-inducible factor (HIF)-1α and HIF-2α,
exhibit both common and unique patterns of downstream target genes that may exert distinct roles in
tumorigenesis. HIF-2α, at least in some tumors, shows a greater oncogenic capacity than HIF-1α, and
its overexpression correlates with poor patient outcome in colorectal carcinoma, melanoma, ovarian
cancer, non-small cell lung cancers, and HCC [20,21]. Accordingly, HIF-2α (not HIF-1α) can favor
proliferation of cancer cells by promoting c-Myc activity, and radio- and chemo-resistance, self-renewal
capability, and stem cell phenotype in non-stem cell populations via Oct-4, Nanog, and c-Myc as well
as by contributing to the maintenance of cancer stem cell (CSCs) properties [19,20]. By contrast, HIF-1α
preferentially plays a role in reprogramming cancer metabolism by activating the transcription of
glycolytic enzyme genes [21].
In the present study we propose that SB3 can affect the behavior of liver cancer cells by increasing
both HIF-1α, at transcription level through a redox-dependent mechanism, and HIF-2α protein levels
by direct and selective NEDDylation/stabilization of HIF-2α, then resulting in up-regulation of related
target genes. These data outline either HIF-2α and NEDDylation as two novel putative therapeutic
targets to interfere with the pro-carcinogenic role of SerpinB3 in the development of HCC.
2. Results
2.1. SerpinB3 Overexpression Up-Regulates HIF-1α and HIF-2α Hepatic Protein Levels
In preliminary experiments we evaluated HIF-α subunits protein levels in total extracts obtained
from the liver of WT, SB3 transgenic—(TG) mice, or SB3 knock out (KO) mice, as well as in in vitro
experiments performed under normoxic conditions in HepG2 cells over-expressing SB3 (H/SB3)
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or transfected with an empty vector (H/3.1). HIF-1α and HIF-2α protein were almost absent in
SB3-KO mice, while were strongly up-regulated in the liver extracts from SB3-TG mice or H/SB3 cells
(Figure 1A,B). In H/SB3 cells HIF-1α over-expression was evident within 24 h and then declined with
the time, whereas HIF-2α levels were up-regulated, in a sustained manner throughout the entire time
course. Accordingly, SB3-TG mice were characterized by a marked and diffuse increase of hepatic
HIF-1α and HIF-2α immune-positivity in hepatocyte cytoplasm and nuclei (Figure 1C) whereas HIF-1α
and HIF-2α positive staining in wild tipe WT mice was limited to few hepatocytes around centrilobular
vein. However, the analysis of HIFs transcripts in vivo and in vitro showed that only HIF-1α mRNA
were significantly increased, while HIF-2α up-regulation did not involve the transcriptional levels
(Figure 1D,E), suggesting a post-translational modifications in SB3-dependent modulation of HIF-2α.
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Figure 1. Analysis of hypoxia-inducible factor (HIF)-1α and HIF-2α transcript and protein levels in 
SerpinB3 (SB3) transgenic mice and SB3 overexpressing HepG2 cells. (A) Western blot analysis of 
HIF-1α and HIF-2α in total extracts of WT mice (WT1—C57Bl6J mice, control for TG mice; WT2—
Balb-C mice, control for knock out (KO) mice), SB3-TG mice (TG 1,2), and knock-out mice for SB3 (KO 
Figure 1. nalysis of hypoxia-inducible factor ( IF)-1α and IF-2α transcript and protein levels in
SerpinB3 (SB3) transgenic ice and SB3 overexpressing ep 2 cells. ( ) estern blot analysis of
HIF-1α and HIF-2α in total extracts of WT mice (WT1—C57Bl6J mice, control for TG mice; WT2—Balb-C
mice, control for knock out (KO) mice), SB3-TG mice (TG 1,2), and knock-out mice for SB3 (KO 1,2);
equal loading was evaluated by re-probing membranes for β-actin. BIORAD Quantity One software
was used to perform the densitometric analysis (data are expressed as Fold Change relative to the
normalized control condition expression). (B) Western blot analysis of HIF-1α, SB3, and HIF-2α in total
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extracts obtained from H/3.1 and H/SB3 at indicated time points. Cells were seeded in normoxic
conditions to obtain the desired sub-confluence level (65%–70%) and after 20 h from plating time course
analysis was performed from 1 h up to 48 h; equal loading was evaluated by re-probing membranes for
α-tubulin. BIORAD Quantity One software was used to perform the densitometric analysis (data are
expressed as Fold Change relative to the normalized control condition expression). (C) IHC analysis
for HIF-1α and HIF-2α performed on liver sections from wild-type (WT) and SB3-TG (TG) mice.
Original magnification as indicated. (D) qPCR analysis of HIF-1α and HIF-2α in WT and TG mice.
Data are expressed as means ± SEM of three independent experiments (** p < 0.01 vs. WT littermates).
(E) qPCR analysis of HIF-1α and HIF-2α transcripts in control HepG2 cells, HepG2 cells transfected with
empty vector pCDNA3.1 (H/3.1), and HepG2 cells over-expressing SB3 (H/SB3). Data are expressed as
means ± SEM of three independent experiments (* p < 0.05 or ** p < 0.01 vs. H/3.1).
2.2. Up-Regulation of HIF-1α by SerpinB3 Is Related to Intracellular Generation of ROS
Although HIF-1α expression may be modulated by several non-hypoxic stimuli (i.e., growth factors,
cytokines, hormones like angiotensin II, thrombin) [22], growing evidence indicates that reactive oxygen
species (ROS) can mediate HIF-1α transcriptional and translational regulation, specifically through
ERK and PI3K/AKT pathways [23,24]. In our experiments, we detected an early and transient increase
in intracellular ROS in H/SB3 cells as compared with control H/3.1 cells (Figure 2A,B). ROS generation
was almost completely abolished by pretreating H/SB3 cells with Rotenone an inhibitor of complex I of
mitochondrial electron chain or by the inhibitor of flavin-dependent enzymes diphenyleneiodonium
(DPI) (Figure 2A,B), while it was unaffected by the addition of the pan-NADPH-oxidase inhibitor
apocynin (APO) (Figure 2A), suggesting that SB3 elicited ROS release by mitochondria. Accordingly,
SB3-dependent up-regulation of HIF-1α and activation of ERK1/2 signaling pathway were prevented
by pretreating H/SB3 cells with either Rotenone or DPI (Figure 2C,D) or with pharmacological inhibitor
of the ERK pathway (PD98059) (Figure 2E) but unaffected by APO (Figure 2C). Rotenone and DPI also
reduced HIF-1α transcript levels (Figure 2F). By contrast, the use of ROS inhibitors was ineffective in
reducing HIF-2α protein levels (Figure 2C).
Interestingly, immunohistochemistry analyses performed on liver serial sections from both SB3-TG
mice and SB3-positive human HCC specimens (in comparison with specimens from normal liver,
Figure S1), showed an intense staining for HIF-1α in the same tissue areas positive for heme-oxygenase-1
(HO-1) (Figure S2A,B), known to be up-regulated by HIF-1α through ROS [25,26]. By contrast,
immune-positivity for SB3, HIF-1α, and HO-1 was almost absent in SB3 KO mice. Moreover, the
highest levels of HO-1 transcripts were found in the sub-class of patients carrying higher (>than
median value) SB3 expression (Figure S2C). Statistical analyses in human specimens also revealed a
positive correlation (Spearman r coefficient = 0.3892, p < 0.01) between HIF-1α and HO-1 transcript
levels (Figure S2D). Furthermore, the highest levels of HIF-1α transcripts were found in the sub-class
of patients characterized by higher levels (> than median value) of HO-1 transcripts (Figure S2E).
Based on the data obtained in human HCCs, we analyzed HCC nodules from murine specimens
obtained from a rodent model of hepatocarcinogenesis based on the administration to mice of the
hepato-carcinogen dimethyl-nitrosoamine (DEN) in combination with the choline-deficient L-amino
acid refined (CDAA) diet. HIF-1α, HO-1 and SB3 transcript levels were all up-regulated in HCC
nodules (Figure S3A–C). Moreover, the highest levels of HO-1 mRNA were found in nodules carrying
higher (> than median value) SB3 expression (Figure S3D). Here again, statistical analyses on HCC
nodules revealed a positive correlation (Spearman r coefficient = 0.4512, p < 0.05) between HIF-1α
and HO-1 transcript levels (Figure S3E), with the highest levels of HIF-1α transcripts detected in HCC
nodules characterized by higher levels (> than median value) of HO-1 transcripts (Figure S3F).
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blot analysis of HIF-1α and HIF-2α protein levels in H/3.1 and H/SB3 cells. In some experiments H/SB3
cells were pretreated with Rotenone (Rot, 2.5 µM), DPI (1 µM), or Apocynin (APO, 250 µM) at the
indicated time. Equal loading was evaluated by re-probed membranes for α-tubulin. BIORAD Quantity
One software was used to perform the densitometric analysis (data are expressed as Fold Change
relative to the normalized control condition expression). (D) Western blot analysis of phosphorylated
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ERK performed on H/3.1 and H/SB3 cells at 6 h. In some experiments, cells were pretreated with
Rotenone (Rot, 2.5 µM) or DPI (1 µM). Equal loading was evaluated by re-probed membranes for
total ERK. BIORAD Quantity One software was used to perform the densitometric analysis (data are
expressed as Fold Change relative to the normalized control condition expression). (E) Western blot
analysis of HIF-1α protein levels in H/3.1 and H/SB3 cells treated or not with ERK pharmacological
inhibitor PD98059. Equal loading was evaluated by re-probing membranes for α-tubulin. BIORAD
Quantity One software was used to perform the densitometric analysis (data are expressed as Fold
Change relative to the normalized control condition expression). (F) qPCR analysis of HIF-1α transcript
levels in control H/3.1 or H/SB3 cells. In the same experiments H/SB3 cells were pretreated with
Rotenone (Rot, 2.5 µM) and DPI (1 µM). Data are expressed as means ± SEM of three independent
experiments. ** p < 0.01 vs. H/3.1 and # p < 0.05 vs. related H/SB3 cells.
2.3. SerpinB3 Induces HIF-2α Stabilization through Selective NEDDylation
According to previous results, we next investigated whether SB3-induced HIF-2α up-regulation
was dependent on post-translational modifications leading to HIF-2α recruitment/stabilization.
As a first approach, according to literature knowledge on HIF-2α changes leading to ubiquitination
and degradation by the 26s proteasome under normoxia [27], we hypothesized that the SB-3 dependent
stabilization of HIF-2α was due to a dysfunction of the ubiquitin-proteasome machinery. Analyzing
the total ubiquitination status of proteins in either total extracts from H/3.1 and H/SB3 or in cytosolic
and nuclear fractions proteins of liver specimens from SB3-TG and WT mice, we found a decrease
of total ubiquitinated proteins when SB3 is overexpressed (Figure 3A). In particular, the analysis of
poly-ubiquitination on Lys48, a specific tag for addressing proteins to proteasome degradation [28,29],
showed a decrease of Lys48-mediated ubiquitination in H/SB3 vs. H/3.1 cells (Figure 3B). Accordingly,
we found a significant increase of the proteasome 26s activity in both H/SB3 cells or SB3-TG mice
(Figure 3C). These results led us to reasonably exclude the ubiquitin-proteasome system as being
involved in HIF-2α post-translational modifications and to consider alternative mechanisms by which
HIF-2α may be stabilized in H/SB3 cells.
Figure 3. Cont.
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Figure 3. Post-translational modifications: ubiquitination of proteins and 26s proteasome activity
versus NEDDylation. (A) Western blot analysis of pan-Ubiquitin in H/3.1 or H/SB3 as well as on
cytosolic and nuclear fractions obtained from WT and SB3-TG mice. Equal loading was evaluated by
re-probing membranes for gliceraldehyde-3-phosphate dehydrogenase (GAPDH) or α-tubulin (for
total extract and cytosolic fraction, respectively) or lamin-A (for nuclear fraction). BIORAD Quantity
One software was used to perform the densitometric analysis (data are expressed as Fold Change
relative to the normalized control condition expression). (B) Western blot analysis of K48-linked
poly-ubiquitination in H/3.1 or H/SB3 cells. Equal loading was evaluated by re-probing the membrane
for GAPDH. BIORAD Quantity One software was used to perform the densitometric analysis (data are
expressed as Fold Change relative to the normalized control condition expression). (C) 26S proteasome
activity obtained from H/3.1 and H/SB3 cells as well as from livers of WT (Wild type mouse-strain
C57BL6J) and SB-TG (Transgenic for human SerpinB3-strain C57BL6J) mice. Data are expressed as
means of Relative Fluorescence Units (RFU) ± SD from three independent experiments (* p < 0.05
vs. control values). (D) Western blot analysis of Neural precursor cell Expressed Developmentally
Downregulated-8 (NEDD8) on total extracts obtained from control H/3.1 cells and H/SB3 cells as well as
on total extract from WT, SB3-TG, and SB3-KO mice showing increased levels of NEDDylated proteins
when SB3 was over-expressed. Equal loading was evaluated by re-probing membranes for GAPDH or
β-actin. BIORAD Quantity One software was used to perform the densitometric analysis (data are
expressed as Fold Change relative to the normalized control condition expression). (E) In vivo IHC
analysis for NEDD8 (global protein neddylation) on WT mice and SB3-TG mice.
We then next focused our attention on the involvement of a new class of proteins called
Ubiquitin-Like proteins (UBLs) since these molecules are structurally and functionally related to
ubiquitin. In particular, the Neural precursor cell Expressed Developmentally Downregulated-8
(NEDD8) conjugation pathway (i.e., NEDDylation) has several analogies with ubiquitination, resulting
in the reversible covalent conjugation of a molecule of NEDD8 to a lysine residue of the substrate
proteins [30]. However, by competing with ubiquitin, the binding of NEDD8 molecules to target proteins
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is reported to promote their stabilization. Emerging literature data reported that the NEDDylation
process was detected in HCC and associated with its poorest prognosis [31]. Along these lines we
next investigated the involvement of a NEDDylation process in SB3-dependent stabilization of HIF-2α.
H/SB3 cells and SB3-TG mice showed a significant increase in total NEDDylated proteins (Figure 3D,E),
an event not associated to a corresponding increase in monomeric NEDD8 (free NEDD8), whose
levels were comparable to those detected in H/3.1 cells and WT littermates (Figure 3D), respectively.
Moreover, total NEDDylated proteins were reduced in SB3-KO mice (Figure 3D) further confirming an
involvement of SB3 in the NEDDylation process.
The lack of changes in monomeric NEDD8 levels was consistent with the increased protein levels
of NEDD8-E1 activating enzyme (NAE1) and of canonical member of the Ubiquitin-activating (E1)
enzyme family (UBE-1) [30,32] in H/SB3 (Figure 4A) as well as of NAE1 transcripts in SB3-TG versus
WT mice (Figure 4B). In addition, IHC analysis revealed higher nuclear immune-positivity for NAE1
in SB3-TG as compared to WT mice as well as a reduction of cytoplasmic and nuclear staining of NAE1
in KO mice (Figure 4C). Immunoprecipitation using antibody against HIF2α and Western blot analysis
using NEDD8 antibody confirm the direct NEDDylation of HIF2α (Figure 4D). In particular, only
in H/SB3 cells a number of additional protein bands for NEDD8 were observed at higher apparent
molecular weight, suggesting NEDDylation and polymerized/aggregated HIF2α. This is not surprising
since NEDDylation of target protein aggregates has been already reported by Maghames et al. [33].
Moreover, HIF-2α protein levels were significantly reduced in H/SB3 cells following pretreatment
with MLN4924 (Figure 4E), the first in class inhibitor of NAE1 and NEDD8 pathway [30,34], or after
effective silencing of NAE1 (Figure 4F, Figure S4A). No modification was observed on HIF-1α protein
levels (Figure S4B). Along these lines, NEDDylation was shown to be aberrant in liver biopsies of
HCC patients in comparison with healthy controls [31,35]. In these patients we also observed a strong
positive correlation between the levels of LKB1 and NEDD8 [31]. Consistent with literature data, IHC
performed on HCC specimens showed HIF-2α immune-positivity in the same areas also positive
for NAE1 and SB3 (Figure 4G), with statistical analyses revealing that the highest levels of NAE1
mRNA were detected in the subclass of HCC patients with highest (> median value) levels of HIF-2α
transcripts (Figure 4H).
Finally, analyzing HCC nodules from rodent model of hepatocarcinogenesis based on the
administration to mice of the hepato-carcinogen dimethyl-nitrosoamine (DEN) in combination with
the CDAA diet, we observed that (i) HIF-2α transcript levels were up-regulated in HCC nodules
(Figure 5A); (ii) there was a positive correlation (Spearman r coefficient = 0.5238, p < 0.01) between
HIF-2α and SB3 (Figure 5B); (iii) the highest levels of NAE-1 transcripts were found in the sub-class of
nodules carrying higher (> than median value) HIF-2α expression (Figure 5C).
Figure 4. Cont.
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Figure 4. SB3-dependent stabilization of HIF-2α through direct NEDDylation. (A) Western blot (WB)
analysis of NEDD8-E1 activating enzyme (NAE1) and ubiquitin-activating (E1) enzyme family (UBE-1)
in control H/3.1 and H/SB3 cells showing increased levels of both protein in H/SB3. Equal loading was
evaluated by re-probing membrane for GAPDH. BIORAD Quantity One software was used to perform
the densitometric analysis (data are expressed as Fold Change relative to the normalized control
condition expression). (B) qPCR analysis of NAE1 transcript levels in WT and SB3-TG mice. Data are
expressed as means ± SEM of three independent experiments (** p < 0.01 vs. WT littermates). (C) IHC
analysis of NAE1 performed on WT (mouse-strain C57BL6J), TG (Transgenic for human SerpinB3-strain
C57BL6J), BC (Wild type mouse-strain Balb/c), and KO (Knock-out for mouse Serpinb3a-strain Balb/c).
Original magnification is indicated. (D) Western blot analysis of NEDD8 after immunoprecipitation
for HIF-2α in H/3.1 and H/SB3 cells at the indicated time points. BIORAD Quantity One software was
used to perform the densitometric analysis (data are expressed as Fold Change relative to the normalized
control condition expression). (E) WB analysis of HIF-2α obtained from H/3.1 or H/SB3 cells. In some
conditions, cells were treated with a specific inhibitor of NAE1 (MLN4924, 3 µM) for 24 h. Equal loading
was evaluated by re-probing membranes for GAPDH. BIORAD Quantity One software was used to
perform the densitometric analysis (data are expressed as Fold Change relative to the normalized control
condition expression). (F) WB analysis of HIF-2α and NAE-1 in H/3.1 and H/SB3 cells, transfected with
non-silencing control (NsC) siRNA or NAE-1 specific siRNA. Equal loading was evaluated by re-probing
membranes for α-tubulin. BIORAD Quantity One software was used to perform the densitometric
analysis (data are expressed as Fold Change relative to the normalized control condition expression).
(G,H) Correlation between HIF-2α and NEDDylation in human hepatocellular carcinoma (HCC) specimens.
(G) IHC analysis for NAE-1, HIF-2α, and SB3 performed on liver sections from HCC patients (grade G2)
showing immune-positive staining for NAE1 and HIF-2α in the same areas also positive for SB3. Original
magnification is indicated. (H) NAE1 and HIF-2α mRNA were analyzed by qPCR in HCC specimens
in relation to low expression (HIF-2α low; n = 17) or high expression (HIF-2α high; n = 17) of HIF-2α
mRNA. The y axis represents the relative mRNA amounts of the normalized gene. Central bars represent
mean and external bars represent SEM. The analysis was performed with Mann–Whitney test showing
significant correlation between HIF-2α and NAE1 (* p < 0.05).
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(A) HIF-2α mRNA were analyzed by qPCR. Data are expressed as means ± SEM (* p < 0.05 vs. CSAA,
## p < 0.01 vs. CDAA). (B) HIF-2α and SB3 mRNA were analyzed by qPCR. Statistical analysis
was performed using Spearman correlation showing a positive correlation between SB3 and HIF-2α.
(C) NAE1 and HIF-2α transcripts were analyzed in relation to low expression (HIF-2α low; n = 17)
or high expression (HIF-2α high; n = 17) of HIF-2α mRNA. The y axis represents the relative mRNA
amounts of the normalized gene. Central bars represent mean and external bars represent SEM.
The analysis was performed with Mann–Whitney test showing a significant correlation between HIF-2α
and NAE1 (* p < 0.05).
2.4. SerpinB3 Up-Regulated HIF-α Subunits Are Biologically Active
We next performed experiments to verify whether SB3-dependent up-regulation of HIF-α subunits
resulted in increased expression of related target genes. According to literature, HIF-1α is mainly
involved in the regulation of glycolytic gene expression during O2 deprivation, whereas HIF-2α
overexpression correlates with poor patient outcome in several human cancers and seems to be
associated with tumor growth and progression [36]. In our experiments we found that SB-3-dependent
HIF-1α up-regulation led to increased expression of genes involved in glycolysis, including Pyruvate
Dehydrogenase Kinase isozyme-3 (PDK3), Pyruvate Kinase Muscle (PKM2), Hexokinase 2 (HK2),
Hexokinase-4 (HK4), and Lactate Dehydrogenase A (LDHA), resulting in increased lactate release in
culture medium of H/SB3 (Figure 6A). Moreover, following specific HIF-1α silencing (Figure S6A), we
observed a significant reduction of HIF-1α target genes as well as of lactate release in culture medium
(Figure 6A). Accordingly, specific silencing of HIF-2α was ineffective on transcript levels of LDHA,
used as most representative glycolytic gene target (Figure S8A).
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Figure 6. HIF-1α-dependent switch to glycolytic phenotype of H/SB3. (A) qPCR analysis of HIF-1α-
target genes (PDK3, PKM2, HK2, HK4, and LDHA) and lactate release in H/3.1 and H/SB3 transfected 
with non-silencing siRNA (NsC) or with specific siRNA for HIF-1α (siHIF-1α). Data are expressed as 
means ± SEM of three independent experiments (* p < 0.05 vs. H/3.1, ** p < 0.01 vs. H/3.1, # p < 0.05 vs. 
related control condition, ## p < 0.01 vs. related control condition). (B) Seahorse Bioscence XF 
Analyzers of OCR (Oxygen Consumption Rate) and ECAR (Extracellular Acidification Rate) 
parameters in H/3.1 or H/SB3 cells. * p < 0.05 vs. H/3.1. Data are expressed as means ± SD of three 
independent experiments. (C) HIF-1α, LDHA, PDK3, and HK2 mRNA were analyzed by qPCR that 
was performed in liver specimens from 67 patients carrying HCC. The use of nonparametric 
Spearman test showed the presence of a positive correlation between HIF-1α and related target genes 
LDHA, PDK3, HK2; Spearman r coefficient and p value were indicated. 
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Figure 6. HIF-1α-depende t switch to gl colytic phenotype of H/SB3. (A) qPCR analysis of
HIF-1α-target genes (PD 3, PKM2, HK2, HK4, and LDHA) and lactate release in H/3.1 and H/SB3
transfected with non-silencing siRNA (NsC) or with specific siRNA for HIF-1α (siHIF-1α). Data are
expressed as means ± SEM of three independent experiments (* p < 0.05 vs. H/3.1, ** p < 0.01 vs.
H/3.1, # p < 0.05 vs. related control condition, ## p < 0.01 vs. related control condition). (B) Seahorse
Bioscence XF Analyzers of OCR (Oxygen Consumption Rate) and ECAR (Extracellular Acidification
Rate) parameters in H/3.1 or H/SB3 cells. * p < 0.05 vs. H/3.1. Data are expressed as means ± SD of three
independent experiments. (C) HIF-1α, LDHA, PDK3, and HK2 mRNA were analyzed by qPCR that
was performed in liver specimens from 67 patients carryi g HCC. The use of nonparametric Spearman
test showed the presence of a positive correlation between HIF-1α and related target genes LDHA,
PDK3, HK2; Spearman r coefficient and p value were indicated.
Moreover, by employing Seahorse analysis to evaluate the real-time measurement of cellular
bioenergetics, we observed an effective and significant reduction of basal oxygen consumption rate
(OCR) as we l as an i c ease in extracellular acidification rat (ECAR) in normoxic H/SB3 versus H/3.1
cells (Figure 6B), events that were reverted by using a specific siRNA for HIF-1α (Figure S6A,B).
By performing qPCR on HCC specimens obtained from a cohort of 67 well characterized patients
employed in a previous study [37], we analyzed transcript levels of both HIF-1α and glycolytic
genes. Statistical analysis extended to all available specimens led us to highlight the existence of a
significant positive correlation between HIF-1α and LDHA, PDK3 and HK2 transcript levels (Figure 6C),
confirming that also in vivo HIF-1α may trigger the glycolytic phenotype switch.
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On the other hand, SB3-dependent HIF-2α stabilization resulted in a reduction of p53 and p21
protein levels in both H/SB3 normoxic cells and SB3-TG mice (Figure 7A). Although the in vivo reported
a decrease in p53 and p21 protein levels in SB3-TG mice may result from more than one mechanism,
in vitro experiments showed that NAE1 specific silencing, which re-established the normal HIF-2α
normoxic degradation, partially abolished the HIF-2α-dependent reduction of p53 and p21 proteins
observed in H/SB3 cells (Figure 7B). In addition H/SB3 cells showed up-regulation of c-myc protein
levels and reduction of p21 and p53 protein levels (Figure S7A,B), events reverted by HIF-2α silencing
(Figure S7C), thus supporting the involvement of HIF-2α in the regulation of cell cycle regulators (p53
and p21) and tumor progression (c-myc). Accordingly, HIF-1α silencing in H/SB3 cells was ineffective
on transcript levels of Myc, p53, and p21 (Figure S8B). Such a SB-3-related and HIF-2α-dependent
regulation of p53, p21, and c-Myc resulted in a shift of cell cycle towards S phase (increase in S
phase ratio up to 96 h), then indicating that H/SB3 cells are more proliferative than control H/3.1 cells
(Figure 7C), with cells in G2/M phase increasing later on at 72 and 96 h. In addition, performing soft
agar colony formation assay [9], the most stringent tests for malignant transformation in cells which
measures the ability of cells to proliferate in semi-solid matrices, we demonstrated that the increase
in colony formation and dimension of H/SB3 was prevented by using the HIF-2α specific inhibitor
(PT-2385 10 µM [38,39], Figure 7D) that efficiently down-regulated in H/SB3 cells HIF-2α and c-myc
protein levels (Figure 7E,F).
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Figure 7. HIF-2α stabilized by SB3 is involved in cell cycle regulation and potentially mediates cancer 
progression. (A) Western blot analysis of p53 and p21 performed on H/3.1 and H/SB3 cells as well as 
in WT and SB3-TG mice. Equal loading was evaluated by re-probing membranes with GAPDH and 
β-actin. BIORAD Quantity One software was used to perform the densitometric analysis (data are 
expressed as Fold Change relative to the normalized control condition expression). (B) Western blot 
analysis of p53, p21, and NAE-1 performed on H/3.1 and H/SB3 cells transfected with non-silencing 
siRNA (NsC) or with specific siRNA for NAE1. Equal loading was evaluated by re-probing 
membranes for β-actin. BIORAD Quantity One software was used to perform the densitometric 
analysis (data are expressed as Fold Change relative to the normalized control condition expression). 
(C) Bar graph charts showing the relative quantity of G0/G1, S, and G2/M ratio in H/SB3 cells 
compared to the H/3.1 control cells as mean ± SD, resulted from cell cycle analysis by flow cytometry 
with FCS Express 4 Flow Research Edition software. This experiment was repeated three separate 
times, and similar results were obtained. (* p < 0.05 or ** p < 0.01 vs. H/3.1 cells). (D) Soft agar colony 
formation assay on H/3.1 and H/SB3 cells. In some experiments H/SB3 cells were treated with HIF-2α 
specific inhibitor (PT-2385, 10 µM). (E,F) WB analysis of HIF-2α (E) and c-myc (F) protein levels 
performed on H/3.1 and H/SB3 cells treated or not with HIF-2α specific inhibitor (PT-2385, 10 µM). 
Equal loading was evaluated by re-probing membranes for β-actin. BIORAD Quantity One software 
was used to perform the densitometric analysis (data are expressed as Fold Change relative to the 
normalized control condition expression). (G) qPCR analysis of HIF-2α and related target genes 
(MMP-9, CXCR4, and EPO) in H/3.1 or H/SB3 cells transfected with non-silencing siRNA (NsC) or 
with specific siRNA for HIF-2α (siHIF-2α) at the indicated time points. Data are expressed as means 
± SEM of three independent experiments (* p < 0.05 and *** p < 0.001 vs. H/3.1; # p < 0.05 and ## p < 
0.001 vs. related control condition). 
2.5. SerpinB3 Was Able to Modulate Angiogenesis 
To integrate the overview of the biological effects of SB3 on HCC cells and tumor 
microenvironment, we evaluated the ability of SB3 to modulate angiogenesis. H/SB3 cells, as 
Figure 7. HIF-2α stabilized by SB3 is involved in cell cycle regulation and potentially mediates cancer
progression. (A) Western blot analysis of p53 and p21 performed on H/3.1 and H/SB3 cells as well as
in WT and SB3-TG mice. Equal loading was evaluated by re-probing membranes with GAPDH and
β-actin. BIORAD Quantity One software was used to perform the densitometric analysis (data are
expressed as Fold Change relative to the normalized control condition expression). (B) Western blot
analysis of p53, p21, and NAE-1 performed on H/3.1 and H/SB3 cells transfected with non-silencing
siRNA (NsC) or with specific siRNA for NAE1. Equal loading was evaluated by re-probing membranes
for β-actin. BIORAD Quantity One software was used to perform the densitometric analysis (data
are expressed as Fold Change relative to the normalized control condition expression). (C) Bar graph
charts showing the relative quantity of G0/G1, S, and G2/M ratio in H/SB3 cells compared to the H/3.1
control cells as mean ± SD, resulted from cell cycle analysis by flow cytometry with FCS Express 4 Flow
Research Edition software. This experiment was repeated three separate times, and similar results
were obtained. (* p < 0.05 or ** p < 0.01 vs. H/3.1 cells). (D) Soft agar colony formation assay on
H/3.1 and H/SB3 cells. In some experiments H/SB3 cells were treated with HIF-2α specific inhibitor
(PT-2385, 10 µM). (E,F) WB analysis of HIF-2α (E) and c-myc (F) protein levels performed on H/3.1 and
H/SB3 cells treated or not with HIF-2α specific inhibitor (PT-2385, 10 µM). Equal loading was evaluated
by re-probing membranes for β-actin. BIORAD Quantity One software was used to perform the
densitom tric analysis (data are expr ssed as Fold Change r lative to the n rmalized control condition
expression). (G) qPCR analysis of HIF-2α and related target genes (MMP-9, CXCR4, and EPO) in H/3.1
or H/SB3 cells transfected with non-silencing siRNA (NsC) or with specific siRNA for HIF-2α (siHIF-2α)
at the indicated time p ints. Data are expressed as means ± SEM of three ind pendent experiments
(* p < 0.05 and *** p < 0.001 vs. H/3.1; # p < 0.05 and ## p < 0.001 vs. related control condition).
Moreover, HIF-2α target genes involved in tumor progression such as metalloproteinase 9
(MMP-9), C-X-C chemokine receptor type 4 (CXCR4, receptor of the chemokine SDF-1), and the more
generic target gene erythropoietin (EPO) are up-regulated in H/SB3 cells and decrease by using HIF-2α
specific siRNA (Figure 7G).
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2.5. SerpinB3 Was Able to Modulate Angiogenesis
To integrate the overview of the biological effects of SB3 on HCC cells and tumor microenvironment,
we evaluated the ability of SB3 to modulate angiogenesis. H/SB3 cells, as compared to H/3.1 cells,
showed increased VEGF intracellular protein levels (Figure 8A), as well as an increased release of
VEGF in the extracellular medium (Figure 8B).
Accordingly, HepG2 naïve cells responded to the addition of human recombinant SB3 (hrSB3
100 ng/mL) led to the phosphorylation and activation of ERK1/2, to HIF1α induction (Figure 8C)
resulting in a time-dependent release of VEGF in culture medium (Figure 8D).
Moreover, by performing tubulogenesis assay on HUVEC cells treated with either hrSB3 or
conditioned medium from H/SB3 cells (CM-H/SB3), we found that SB3 was able to induce tubes
formation (Figure 8E, human recombinant VEGF used as positive control), indicating that SB3 can act
as a paracrine mediator able to favor angiogenesis in the tumor microenvironment.
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Figure 8. SB3 induces angiogenesis. (A) WB analysis of VEGF perfor ed on H/3.1 and H/SB3 cells at
indicated time points (time-course analysis started after 20 h from cell seeding). BIORAD Quantity One
software was used to perform the densitometric analysis (data are expressed as Fold Change relative
to the normalized control condition expression). (B) VEGF ELISA assay on H/3.1 and H/SB3 at 72 h.
Data are expressed as means ± S.D of three independent experiments (* p < 0.05 vs. H/3.1). (C) WB
analysis of pERK1/2 and HIF1α performed on HepG2 naïve cells treated with human recombinant SB3
(hrSB3, 100 ng/mL) at indicated time points. Equal loading was evaluated by re-probing membranes
with total ERK or β-actin, respectively. BIORAD Quantity One software was used to perform the
densitometric analysis (data are expressed as Fold Change rel tive to th normalized control condition
expressio ). (D) VEGF ELISA assay on HepG2 naïve treated with hrSB3 at indicated time points.
Data are expressed as means ± S.D of three independent experiments (* p < 0.05 or ** p < 0.01 vs. HepG2
control cells). (E) HUVEC tubulogenesis assays were performed in solidified basement membrane
matrix (Matrigel; BD Biosciences). HUVECs were seeded and treated or not with the hrSB3 (100 ng/mL)
as well as with conditioned medium collected from H/3.1 control cells (CM-C H/3.1) or H/SB3 cells
(CM-H/SB3) after 72 h (VEGF-A 10 ng/mL or 50 ng/mL was used as positive control). After 14 h, tubular
structures were microscopically examined and photographed (Leica, Wetzlar, Germany). (F) SB3 and
VEGF mRNA were analyzed by qPCR that was performed in liver specimens from 67 patients carrying
HCC. The use of non-parametric Spearman test showed the presence of a positive correlation between
VEGF and SB3 (* p < 0.05).
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Finally, we performed an additional qPCR analysis for SB3 and VEGF transcript levels in liver
specimens from 67 patients carrying HCC. The use of non-parametric Spearman test showed the
presence of a positive and significant correlation (Spearman r coefficient = 0.2923, p < 0.05) between
these transcripts, then supporting the hypothesis of a strict relationship between angiogenesis and SB3
(Figure 8F).
3. Discussion
The present study provides evidence supporting the novel concept that SB3, in the contest of
tumor microenvironment, can operate as a paracrine mediator able to differentially up-regulate HIF-1α
(i.e., through redox-dependent increased transcription) and HIF-2α (through selective NEDDylation)
protein levels in a hypoxia-independent manner.
The early and transient up-regulation of HIF-1α protein levels in H/SB3 cells was correlated to
SB3-dependent increased intracellular ROS levels (likely released by mitochondria). Up-regulation of
HIF-1α by ROS has been extensively described to occur early in cells exposed to hypoxia [24–26,40], but
a growing body of evidence also suggests that ROS and related mechanisms and pathways can mediate
HIF-1α up-regulation even under normoxia [23] through different signaling pathways, including
ERK and PI3K/Akt pathways. According to literature data, results obtained in this study showed
that transcriptional regulation of HIF-1α is more likely related to ROS-dependent activation of the
ERK pathway.
Even more relevant, this study provides the novel message that SB3 can trigger selective
NEDDylation of HIF-2α as a mechanism able to stabilize and increase its protein levels. It is well
known that HIF-α subunits are rapidly and continuously degraded in normoxia as a consequence of
hydroxylation on proline residues (Pro402-564 for HIF-1α and Pro405-531 for HIF-2α) in their ODD
(Oxygen-dependent Degradation Domain) domains [41]. This usually leads toα-subunit ubiquitination
by Von Hippel Lindau (VHL)-ubiquitin-E3 ligase and consequent proteasomal degradation. Our data
from in vivo and in vitro experimental models indicate that the prevention of HIF-2α degradation
due to post-translational modification is not associated to ubiquitin-proteasome system dysfunction.
In particular, poly-ubiquitination on K48-lysine residues, which is an event targeting protein for
proteasome-mediated degradation [28,29], was decreased in H/SB3 cells, as a consequence of the
increased activity of proteasome machinery.
Accordingly, we next considered other post-translational modifications of cellular proteins, by
focusing our attention to the involvement of NEDD8 and NEDDylation process in the stabilization of
proteins with essential regulatory roles [30]. Concerning NEDD8-related target proteins, the substrates
were divided into cullins and non-cullins, including p53, MDM2, pVHL, HIF-1α/HIF-2α, HuR, and
more [42,43]. Cullins are a major family of proteins that are subunits of the E3 ligase machinery,
which brings together E2 ubiquitin-conjugating enzymes and substrates that have been targeted for
degradation. In relation with HIFs, Ivan and colleagues [44] reported the involvement of Cullin 2
(Cul2) in the ubiquitin-ligase complex that binds pVHL, leading to HIF-1α poly-ubiquitination and
its consequent O2-dependent degradation. Controversial data have been reported about the role of
NEDDylation in the regulation of HIF-1α protein levels: Curtis and colleagues [45] reported that
NEDDylation of Cul2 facilitates HIF-1α poly-ubiquitination and proteasome degradation; indeed the
inhibition of Cullin-2 NEDDylation by using the NAE1 pharmacological inhibitor that resulted in
HIF-1α stabilization, activation of HIF promoter, and up-regulation of HIF-target genes in human
epithelial intestinal cells and HeLa cells. By contrast, a study from Russel and Ohh [46] reported that in
different cancer cell lines direct NEDDylation of pVHL may negatively regulate HIF-1α ubiquitination
leading to its stabilization. Alternatively, in another study by Ryu J-H and colleagues [47], the authors
reported that HIF-1α expression and activity were inhibited by knocking down NAE1-mediated
NEDD8 conjugation but enhanced by ectopically expressing NEDD8. Moreover, in this study, HIF-1α
and HIF-2α were found to be covalently modified by NEDD8 [47]. However, these results were
obtained using HEK293 overexpressing HIF-1α, HIF-2α, and NEDD8 and maintained under normoxic
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condition or in NEDD8-overxpressing cells incubated in hypoxic conditions. Although in our conditions
SB3-dependent HIF-1α stabilization under normoxia was clearly ROS-dependent, HIF-1α protein
levels were unchanged following NAE1 silencing (Figure S4B), then reasonably excluding a role for
SB3-related NEDDylation in HIF-1α stabilization.
On the other hand, our findings demonstrate the involvement of NEDD8 and NEDDylation process
in the SB3-dependent and hypoxia-independent stabilization of HIF-2α. Immuno-histochemical and
Western blot analyses on SB3-TG mice or H/SB3 cells revealed increased levels of NEDDylated proteins.
This event was not associated to up-regulation of monomeric NEDD8, but rather to a SB3-dependent
over-expression of the NEDD8-activating enzyme 1 (NAE1). The analysis of HCC specimens as well as
of nodules obtained from mice undergoing DEN/CDAA showed a positive and significant correlation
between NAE1 and HIF-2α transcript levels was detected, a novel finding which is consistent with
data reporting a significant increase in global NEDDylation in human HCC that, in turn, is associated
with poorest prognosis [31]. Accordingly, the inhibition of NAE1 by using its specific pharmacological
inhibitor MLN4924 as well as NAE1 silencing by employing an efficient and selective siRNA, led to
the selective reduction of HIF-2α protein levels.
In our experimental models, the ability of SB3 to up-regulate and stabilize HIF-1α in a
redox-sensitive manner as well as to directly stabilize HIF-2α through NEDDylation resulted in
their nuclear translocation (Figure S5) and in selective up-regulation of specific target genes. HIF-1α
and HIF-2α are known to exhibit common properties, including a partial sequence identity, the
interaction with ARNT and the binding to HRE sequences to induce the expression of common target
genes like GLUT1, VEGF-A, and ADM-1. However, literature data also indicate that they can differ
significantly for other aspects [36], specifically in their transactivation domains, implying they also
have unique target genes [27]. In particular, HIF-1α exclusively regulates glycolytic gene expression,
whereas HIF-2α has been shown to promote tumor growth in a renal carcinoma xenograft model [48,49]
and invasiveness (through up-regulation of MMP-2, MMP-9, and PAI-1). In the present study we
demonstrated that H/SB3 cells display up-regulation of HIF-1α target genes involved in anaerobic
glycolysis (PDK3, PKM2, HK2, HK4, and LDHA) followed by a reduction of OCR, an increase in
ECAR parameters as well as an increased release of lactic acid, suggesting that SB-3-dependent aerobic
stabilization of HIF-1α could potentially drive glycolysis in tumors without dependence on a hypoxic
environment. On the other hand, referring to the partially antithetic activity of HIF-1α and HIF-2α,
it has been reported that HIF-1α can lead to cell cycle arrest in hypoxic cells counteracting c-Myc
activity [50]. By contrast, cells over-expressing HIF-2α exhibit enhanced c-Myc activity and a more
rapid entry in S-phase [36]. Accordingly, here we produced evidence of up-regulation of c-myc protein
levels and reduction of p21 and p53 protein levels in H/SB3 cells, events reverted by HIF-2α silencing.
This SB-3-related and HIF-2α-dependent regulation of p53, p21, and c-Myc resulted in a shift of cell
cycle towards S phase (increase in S phase ratio), that may justify the more proliferative phenotype of
H/SB3 cells. These results are consistent with data obtained from soft-agar colony formation assay that
demonstrated an HIF-2α-dependent increase in colony formation and dimension on soft-agar of H/SB3
compared to control H/3.1 cells. Moreover, SB3-dependent NEDDylation/stabilization of HIF-2α in
H/SB3 normoxic cells resulted in an over-expression of HIF-2α target genes involved in invasiveness
and metastasis (MMP-9 and CXCR-4).
4. Materials and Methods
4.1. Materials
Enhanced chemiluminescence (ECL) reagents, nitrocellulose membranes (Hybond-C extra), and
secondary Cy3-conjugated antibodies were from Amersham Pharmacia Biotech Inc. (Piscataway, NJ,
USA). The following antibodies were used: anti-HIF-1α (NB100-479) and anti-HIF-2α (NB100-122)
from Novus Biologicals; anti SB3 from Xeptagen; anti-total UbQ (sc-8017), anti-LaminA (sc-20680),
anti-p53 (sc-6243), anti-p21 (sc-817), anti-gliceraldehyde-3-phosphate dehydrogenase (GAPDH)
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(sc-20357), and anti-ERK (sc-94) from Santa Cruz Biotechnology; anti-NEDD8 (ab81264) from Abcam;
anti-NAE-1 (AP13067c) from Abgent; anti-UBE-1 (BML-PW8395-00251) from ENZO Life Sciences;
anti-HO-1 (MA1-112) from Invitrogen; anti-Ub-48 (05-137) from Millipore; anti-P-ERK (#4696) from
Cell Signaling Technology; anti-α-tubulin (T9026) and anti-β-actin (A5441) from Sigma Aldrich.
DMOG (Dimethyloxalylglycine) and all other reagents of analytical grade were from Sigma Aldrich.
HiPerfect Transfection Reagent was from Qiagen. Lactate Colorimetric/Fluorometric assay kit was
from Biovision Incorporation.
4.2. Methods
4.2.1. Cell Lines and Culture Conditions
HepG2 cells (from ATCC, USA) were stably transfected with the human SB3 cDNA to over-express
SB3 (H/SB3) or with the empty vector (pCDNA3.1) alone (H/3.1) as previously described [9]. H/SB3
cells, maintained in Dulbecco’s modified Eagle’s medium as previously described [9] were seeded in
normoxic conditions to obtain the desired sub-confluence level (65%–70%) and after 20 h from plating
time course analysis was performed from 1 h up to 48 h.
4.2.2. Mouse Models
The study was carried out on 12–14 week old C57BL/6 mice made transgenic for human SerpinB3,
selectively expressing SerpinB3 in hepatocytes (n = 6) (with the initial colony kindly provided by
Prof. Cassani, Tecnogen, Caserta, Italy) [12], that was already described and employed in previous
studies [12,51]. Wild type C57BL/6 mice of similar age (n = 6) were used as controls.
Serpinb3a knockout mice (kindly provided by Dr. Gary Silverman and Dr. Cliff J. Luke, University
of Pittsburg, Children’s Hospital, Pittsburg, PA) were used (n = 5) as an additional negative control
murine model. All animals were kept under specific pathogen-free conditions and maintained with
free access to pellet food and water at the Animal Care Facility of the Experimental Surgery Division of
the University of Padua. Animals experiments and protocols, approved by the local Ethical committee and
by the Italian Ministry of Health (the ethical code is N.61319), complied with national ethical guidelines
for animal experimentation and were conducted in accordance with the Principles of laboratory animal
care (NIH publication no. 85–23, revised 1985; http://grants1.nih.gov/grants/olaw/references/phspol.htm).
In dedicated experiments wild type C57BL/6 mice were submitted to (a) an established liver
carcinogenic protocol involving a single administration of diethylnitrosamine (DEN, 25 mg/kg bw, i.p.)
at the age of 2 weeks to mice that were fed then from the age of 6 weeks on a choline-deficient
L-aminoacid-defined (CDDA) diet (Laboratorio Dottori Piccioni, Gessate, Italy) for additional
26 weeks [52] (b) a CDAA diet only or (c) a choline-sufficient L-aminoacid-defined (CSSA) diet
(Laboratorio Dottori Piccioni, Gessate, Italy) for 26 weeks starting from the age of 6 weeks. Mice were
kept under specific pathogen-free conditions and maintained with free access to pellet food and
water. Liver samples were obtained and immediately used/processed for morphological or molecular
biology analyses or frozen and thereafter maintained at −80 ◦C for further analysis. These experiments
complied with EU and national ethical guidelines for animal experimentation and experimental
protocols were approved by the Animal Ethic Commitee of University of Oriental Piedmont, Novara,
Italy and Italian Ministry of Health.
4.2.3. Patients and Samples
Human HCC specimens were obtained, under written informed consent, at the time of surgery
in 67 patients with underlying cirrhosis of different etiology. Clinicopathologic and molecular
characteristics as well as follow-up procedures applied to these patients were described in a previous
study [37]. All the patients underwent surgical resection as first-line therapy without pre-operative
anticancer treatment and distant metastases. Tumor samples were either formalin fixed and paraffin
embedded or immediately frozen at −80 ◦C for transcript analysis. The use of human material
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conforms to the ethical guidelines of the 1975 Declaration of Helsinki and all experimental protocols
were approved by the University of Padua Ethical Committee. Informed consent was obtained from
all participants included in this study according to the committee regulations.
4.2.4. Quantitative Real-Time PCR (qPCR)
RNA extraction, complementary DNA synthesis, quantitative real-time PCR (qPCR) reactions
were performed as previously described [13,37]. The amplification mix was prepared using Roche
LightCycler FastStart DNA MasterPLUS SYBR Green I kit following manufacturer’s instructions and
real-time PCR was performed using LightCycler instrument. Oligonucleotide sequence of primers used
for RealTime qPCR were reported in Table 1. GAPDH was used as internal reference and co-amplified
with target samples using identical qPCR conditions. Samples were run in triplicate and mRNA
expression was generated for each sample.
Table 1. Primers for quantitative real-time PCR (Q-PCR).
Primer Sense Reverse
Human HK4 5’-CGCCAAGAAGGAGAAGGTAGAGC-3’ 5’-AAGTCCCCGACTTCTGAGCC-3’
Human PKM2 5’-GCTGTCTGGAGAAACAGCCA-3’ 5’-GTGACTTGAGGCTCGCACAA-3’
Human HK2 5’-AAATGGAGCGAGGTCTGAGC-3’ 5’-CCCACTTCCCATTCCGAACA-3’
Human PDK3 5′-ATTCAATGCCAAAGCGCCAG-3′ AGCAGGGTAGCCCTCTTTT-3′
Human LDHA 5′-CATGGCCTGTGCCATCAGTA-3′ GAAAAGGCTGCCATGTTGG-3′
Human EPO 5′-GAGCCCAGAAGGAAGCCATC-3′ CGGAAAGTGTCAGCAGTGA-3
Humman CXCR4 5′-TCCATTCCTTTGCCTCTTTTGC-3′ CGGAAACAGGGTTCCTTCAT-3′
Human MMP9 5’-TTCAGGGAGACGCCCATTTC-3’ AAACCGAGTTGGAACCACGA-3’
Human NAE-1 5’-GCAAACAAAAACAAATGAAGCCAG-3’ 5’-TTTCAGTTCCTGTGGCTGTTG-3’
Murine NAE-1 5’-AGCGGAGAAGATGCTGGAAAC-3’ 5’-CTGGACTCTCTTCCACAAAACT-3’
Murine HIF-1α 5’-TCAAGTCAGCAACGTGGAAG-3’ 5’-TATCGAGGCTGTGTCGACTG-3’
Murine HIF-2α 5’-CTAAGTGGCCTGTGGGTGAT-3’ 5’-GTGTCTTGGAAGGCTTGCTC-3’
Human HIF-1α 5’-CCACCTATGACCTGCTTGGT-3’ 5’-TATCCAGGCTGTGTCGACTG-3’
Human HIF-2α 5’-TTGATGTGGAAACGGATGAA-3’ 5’-GGAACCTGCTCTTGCTGTTC-3’
Human HO-1 5’-ATGACACCAAGGACCAGAGC-3’ 5’-GTGTAAGGACCCATCGGAGA-3’
Human GAPDH 5′-TGGTATCGTGGAAGGACTCATGAC-3′ 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′
Murine GAPDH 5′-TGGAAAGCTGTGGCGTGAT-3′ 5′-TGCTTCACCACCTTCTTGAT-3′
4.2.5. NAE1 and HIFs Silencing by Small RNA Interference
RNA interference experiments to knockdown NEDD8 activating enzyme 1 (NAE1), HIF-2α,
and HIF-1α expression in HepG2 cells transfected with empty vector or over-expressing SB3 were
performed using siRNA duplex and HiPerfect Transfection reagent (Qiagen Italia, Milano, Italy)
according to manufacturer’s instructions up to 72 h, as previously described [13,18]. The following
target sequences were used:
NAE1: 5′-AAGTAGTGTGTTAATGATTGA-3′
HIF-2α: 5′-CCCGGATAGACTTATTGCCAA-3′
HIF-1α: 5′-AGGAAGAACTATGAACATAAA-3′
4.2.6. Western Blot Analysis
Total cell lysates or nuclear vs. cytosolic extracts were subjected to sodium dodecyl
sulfate-polyacrylamide gel-electrophoresis on 20%, 12%, 10%, or 7.5% acrylamide gels as previously
described [13,18]. Sample loading was evaluated by reblotting the same membrane with the
un-phosphorylated form of protein or with β-actin, α-tubulin, or GAPDH antibody. In some
experiments, protein levels in culture medium obtained from H/3.1 or H/SB3 cells were evaluated by
an immunoprecipitation procedure, as described previously [53].
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4.2.7. Immunohistochemistry Analysis
Paraffin liver sections derived from wild-type mice, SB3 transgenic mice or Sb3a knockout
mice as well as human HCC specimens, were immune-stained as previously reported [13,54] by
employing 2 µM thick paraffin sections. Immune staining was performed by employing monoclonal or
polyclonal antibodies raised against HIF-1α (dilution 1:100), HIF-2α (dilution 1:200), NEDD8 (dilution
1:200), NAE-1 (dilution 1:300), HO-1 (dilution 1:300), as well as polyclonal SB3 antibody (dilution
1:500, for mice specimens) or monoclonal SB3 antibody (dilution 1:50, for human HCC specimens).
Endogenous peroxidase was blocked by 3% hydrogen peroxide and antigen retrieval was obtained
by microwave; immune positivity was revealed by means of EnVision, HRP-labeled System (DAKO)
using 3′-diaminobenzidine as substrate.
4.2.8. Detection of Intracellular Generation of ROS
Detection of ROS generation in cultured cells was performed by using the semi-quantitative
2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) technique as previously described [13,18].
H/3.1 or H/SB3 cells (105 cells/well) were seeded in 12-well culture plates and, in some experiments,
pretreated with either Apocynin (APO, 250 µM), Rotenone (Rot, 2.5 µM), or DPI (1 µM). Intracellular
generation of ROS was detected using 2′,7′-dichlorodihydrofluorescein diacetate which, in the presence
of ROS, is converted to a fluorescent derivative. Fluorescent cells were then analyzed using a Leica
fluorescence microscope (DMI 4000 B model). Alternatively, detection of ROS generation was evaluated
by combining DCFH-DA technique and flow cytometric analysis. Cells were seeded in P35 dishes
(5 × 105 cells/dish) and exposed to hrSB3 alone or hrSB3 plus Rotenone 2.5 µM or DPI 1 µM before
addition of DCFH-DA (15 min of incubation in the dark). After DCFH-DA exposure, the wells were
washed twice with PBS and cells were collected following trypsinization, briefly centrifugated and
then resuspended in PBS. Green fluorescence (FL1) was detected on least 5000 cells per sample using
a FACScan equipped with a 488 nm argon laser and finally analyzed by employing the CellQuest
software (Becton-Dickinson, Milano, Italy).
For comparative purposes HepG2 control cells were treated with 50 µM H2O2 under normoxic
conditions (as positive control).
4.2.9. Lactic Acid Release in Culture Medium
H/3.1 or H/SB3 cells were seeded in 6-well culture plates (106 cells per well), up to 48 h. Lactic acid
release in culture medium was evaluated, according the manufacturer’s instructions, by colorimetric
assay kit supplied by Biovision Incorporated (155 S Milpitas Blvd. Milpitas, CA 95035, USA).
4.2.10. Measurements of Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR)
Cellular metabolic profile was determined using a Seahorse XF24 Extracellular Flux Analyzer
(Seahorse Biosciences, USA), providing real-time measurements of oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR), as previously described [31]. HepG2 cells transfected with
empty vector or over-expressing SB3 were seeded in collagen I coated XF24 cell culture microplates
(Seahorse Bioscience), at 1.5 × 104 cells per well. After 24 h, growth medium was removed and replaced
with 500 µL of assay medium prewarmed to 37 ◦C, composed of DMEM without bicarbonate containing
1 mM sodium pyruvate, 2 mM L-glutamine, and left at 37 ◦C in a CO2-free cell incubator. Measurements
of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were performed after
equilibration in assay medium for 1 h. After an OCR and ECAR baseline measurement, sequential
injections through ports in the XF Assay cartridges of pharmacologic inhibitors: Oligomycin (1 mM),
an inhibitor of ATP synthase, which allows a measurement of ATP-coupled oxygen consumption
through oxidative phosphorylation (OXPHOS); carbonyl cyanide 4-trifluoromethoxy-phenylhydrazone
(FCCP) (300 nM), an uncoupling agent that allows maximum electron transport, and therefore a
measurement of maximum OXPHOS respiration capacity; and finally Rotenone (2 µM, a mitochondrial
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complex 1 inhibitor) plus Antimycin (1 µM) were performed and changes in OCR and ECAR
were analyzed.
4.2.11. Proteasome Activity Assay
The in vitro assay of 26S proteasome activities was performed as previously described [55]. Cells
or liver samples were collected in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, and 2 mM ATP) without protease inhibitors. Lysate was centrifuged at 10,000 g for
10 min at 4 ◦C. Approximately 15–25 µg of total protein of cell lysates were collected in proteasome
activity assay buffer (250 mM HEPES, pH 7.5, 5 mM EDTA, 0.5% NP40, 0.01% SDS, and 2 mM ATP)
and were transferred to a UV Flat Bottom 96-well microtiter plate (Thermo Fisher Scientific, Waltham,
MA, USA) with 20 µM of the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC (Enzo BML-P802-0005)
to measure the caspase-like activity of the proteasome. Free AMC liberated by the substrate hydrolysis
was quantified for 2–3 h at 37 ◦C. Fluorescence (380 nM excitation, 460 nM emission) was monitored
using a SpectraMax M2 plate reader (Molecular Devices, CA, USA). Preliminary experiments with
control cells indicated that reaction rates were linear for at least 4 h. The data were plotted as Relative
Fluorescence Units (RFU).
4.2.12. Cell Cycle Analysis
H/3.1 or H/SB3 cells were seeded in culture plates (5 × 105 cells per well, 35 mm Ø), up to
96 h. At indicated time point cells were trypsinized, centrifugated at 1000 rpm for 10 min and fixed
with ethanol (ET-OH 70%), then treated with RNAsi for 30 min (final concentration 0.4 mg/mL) and
stained with propidium iodide (final concentration 0.184 mg/mL). The cell cycle was analyzed by flow
cytometry and quantified with FCS Express 4 Flow Research Edition software.
4.2.13. Soft Agar Colony Formation
H/3.1 and H/SB3 cells (10,000/well) were seeded on plates coated with soft agar (40% agarose, 40%
Dulbecco’s modified Eagle’s medium (DMEM), 20% FBS). Cells were incubated for 12 days in a 5%
CO2 atmosphere and then colony formation was evaluated employing phase-contrast microscopy, as
previously described [9].
4.2.14. In Vitro Angiogenesis
The angiogenic effect of human recombinant SerpinB3 was assayed by evaluating tube formation
with HUVECs seeded on BD Matrigel Matrix Growth Factor Reduced (BD 354230) or BD Matrigel
Matrix (as positive control for the technique, BD 354234), as previously described [56], with some
modifications. Briefly, 100 µL of Matrigel was added per well of 48-well tissue culture plates and
allowed to gel at 37 ◦C for 30 min. HUVECs (2 × 104 cells/well) were loaded on the top of the Matrigel
in medium M199 supplemented with 10% serum, with or without human recombinant VEGF (positive
control, 10 ng/mL), SerpinB3 (100 ng/mL) or conditioned medium. After 14 h photographs were taken
with digital CCD Hamamatsu ORCA camera linked to an inverted microscope (Leica Microsystems).
4.3. Statistical Analysis
Data presented in bar graphs (i.e., for cell culture experiments from average data of at least
three independent experiments) represent means ± SEM. Data related to autoluminograms and
immunofluorescence images were obtained from at least three experiments providing homologous
results. Student’s t-test or ANOVA test for analysis of variance were employed to evaluate statistical
significance of data (with p < 0.05 value considered as significant).
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5. Conclusions
In conclusion, we propose that SB3 (Figure 9), whose expression is significantly associated with
the worst clinical outcome in HCC patients [37], potentially acts as a paracrine mediator able to affect
the behavior of surrounding normal and cancer cells by differently modulating, independently on
hypoxic microenvironment, the expression of HIF-1α and HIF-2α proteins, with HIF-1α facilitating
cell survival in a harsh microenvironment by inducing early cellular metabolic switch to glycolytic
phenotype and HIF-2α potentially promoting proliferation and tumor progression.
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carcinoma [31,42,57,58]. Accordingly, targeting the NEDDylation pathway is representing a potential 
and attractive anticancer therapeutic strategy. Of relevance, the NEDD8-activating enzyme (NAE) 
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in a harsh microenvironment by inducing early cellular metabolic switch to glycolytic phenotype,
whereas selective NEDDylation and nuclear translocation of HIF-2α can promote proliferation and
tumor progression.
In particular, the emerging evidence related to the biological activity of SerpinB3 in tumor
microenvironment is of relevance since it outlines two putative novel therapeutic targets involved
in cell proliferation and HCC development and progression. Neddylation, a post-translational
modification that adds an ubiquitin-like protein NEDD8 to substrate proteins, then affecting their
stability as well as their subcellular localization, conformation, and function, has been reported to be
over-activated in different human cancers, including lung cancer, intrahepatic cholangiocarcinoma,
HCC, colorectal cancer, glioblastoma, nasopharyngeal carcinoma, and esophageal squamous cell
carcinoma [31,42,57,58]. Accordingly, targeting the NEDDylation pathway is representing a potential
and attractive anticancer therapeutic strategy. Of relevance, the NEDD8-activating enzyme (NAE)
inhibitor MLN4924 has been demonstrated to exhibit potent antitumor activity and to be well-tolerated
in preclinical studies [34,42,59]. Actually, MLN4924 entered into phase I/II/III clinical trials for patients
suffering from solid tumors other than HCC as well as hematologic malignancies [42]. In particular,
33 clinical trials have been enrolled in clinicaltrials.gov website (https://www.clinicaltrials.gov/), and
eight completed phase I clinical trials demonstrated that MLN4924 is safe and feasible. Concerning
HCC, a recent study from Yang and colleagues has reported a correlation between NAE1 expression
and histologic grade, tumor size as well as clinical stage of HCC in patients. Moreover, they showed
that the overall survival rate was significantly lower in HCC patients with higher expression of NEDD8
or NAE1, highlighting an association with poor patient prognosis [60].
On the other hand, the intra-tumor hypoxic microenvironment is a condition associated
with increased malignancy, poor prognosis, and resistance to clinical treatment (radiotherapy and
chemotherapy) [36,61]. However, divergent observations have arisen in separate analysis of some
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human cancers about the prognostic significant of HIF-1α and HIF-2α; for example, HIF-1α expression
has been associated to either better or worst prognosis, depending on tumor type (i.e., renal and
non-small cell lung cancers) [36]. Concerning HCC, growing evidence shows a correlation between
HIF-2α expression and clinic-pathological features, including tumor grade, venous invasion, necrosis,
intrahepatic metastasis, and capsule infiltration, with a significant increase of the overall survival
rates of patients with HIF-2α-negative tumors. Accordingly, in a previous study we provided data
indicating that in HCC specimens the paired expression of SerpinB3 and HIF-2α transcript levels
was significantly correlated, with high levels of both transcripts being detected in HCC specimens
from patients that experienced early HCC recurrence. Furthermore, a multivariate analysis with
Cox’s regression indicate HIF-2α as an independent significant prognostic factor [61]. Along these
lines, perturbation of HIF-2α levels in HCC may represent a novel molecular-targeted therapy for
HCC. Actually, PT2385 is a first-in-class, selective small-molecule inhibitor of HIF-2α able to act by
blocking HIF-2α/ARNT heterodimerization and inhibiting HIF-2α target genes expression. Preclinical
results on a mouse xenograft model of clear cell Renal Cell Carcinoma (ccRCCs), demonstrated
that PT2385 has potent antitumor efficacy in terms of decreased expression of HIF-2α target genes,
decreased circulating human VEGF-A protein, and increased tumor cell apoptosis as well as tumor
regression [38]. More recently, three additional clinical trials have started on glioblastoma and ccRCCs
(https://www.clinicaltrials.gov/) but still no human data are available on the use of PT2385 in relation
to HCC. Data in the present study, showing that SerpinB3-dependent increased HIF-2α stabilization
through direct NEDDylation, should then encourage to consider both HIF-2α and NAE1 as putative
novel targets for a selective therapeutic strategy designed to interfere with HCC progression.
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